#ESMO26 1003O: Ph1 study of IM96, a #GCC-targeted #CART therapy, in heavily pre-treated #CRC (4L+). ORR 42%, with G3 CRS in 10%. Promising efficacy in a setting with few options. #ColonCancer @myESMO @OncoAlert